Implementation of <i>DPYD</i> and <i>UGT1A1</i> Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial
Pretreatment <i>DPYD/UGT1A1</i> testing and dose reduction was feasible, enabling clinicians to make the appropriate chemotherapy dose reductions, reducing occurrence of adverse outcomes. <i>DPYD/UGT1A1</i> testing is an important precision oncology approach to optimize patient safety.
Authors
- Glenda Hoffecker (ORCID: https://orcid.org/0000-0002-7199-2196)
- Donna Capozzi
- Mari Cayabyab (ORCID: https://orcid.org/0000-0002-5345-6154)
- Nevena Damjanov (ORCID: https://orcid.org/0000-0002-4195-7277)
- Abigail Doucette (ORCID: https://orcid.org/0000-0002-6646-433X)
- Sony Tuteja (ORCID: https://orcid.org/0000-0001-7007-3289)
- Rachel Hatch (ORCID: https://orcid.org/0000-0002-4903-7766)
- Avni Santani (ORCID: https://orcid.org/0000-0003-2871-4307)
- Margaret Harr (ORCID: https://orcid.org/0000-0002-1213-006X)
- Drew Watson (ORCID: https://orcid.org/0000-0003-4329-7003)
- Ursina Teitelbaum (ORCID: https://orcid.org/0000-0002-6602-7252)
- Peter Gabriel (ORCID: https://orcid.org/0000-0002-3772-9669)
- Lisa A. Varughese (ORCID: https://orcid.org/0000-0002-7995-2957)
- Randall A. Oyer (ORCID: https://orcid.org/0000-0001-7554-4166)
- Håkon Håkonarson (ORCID: https://orcid.org/0000-0003-2814-7461)
- Ryan Massa (ORCID: https://orcid.org/0000-0002-7147-6538)
- Xingmei Wang (ORCID: https://orcid.org/0000-0002-0281-0336)
- Victoria Wittner (ORCID: https://orcid.org/0009-0002-4886-2171)
- Jean De Dieu Ndayishimiye
- Nandi J. Reddy
Institutions
- Children's Hospital of Philadelphia (US)
- Hospital of the University of Pennsylvania (US)
- Lancaster General Hospital (US)
- Translational Therapeutics (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1200/po-25-00086
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35